Evolus director granted 45,559 RSUs

GILL DAVID N reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 02/19/2026 - 08:57 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

GILL DAVID N reported acquisition or exercise transactions in this Form 4 filing.

Evolus, Inc. director David N. Gill received a grant of 45,559 restricted stock units (RSUs) of common stock. The award was made at no cash cost per share and will vest in full on the one-year anniversary of February 17, 2026, if he remains in continuous service. Following this grant, Gill directly holds 86,887 shares or share-equivalent RSUs.

Insider Trade Summary

Grant/Award: 45,559 shares

Grant/Award 1 txn

Insider GILL DAVID N

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	45,559	$0.00	$0.00

Holdings After Transaction: Common Stock — 86,887 shares (Direct)

Footnotes (1)

1. F1. Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 17, 2026, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Evolus (EOLS) report for David N. Gill?

Evolus reported that director David N. Gill received a grant of 45,559 restricted stock units. These RSUs convert into common shares on vesting and increased his direct holdings to 86,887 share-equivalent units, reflecting an equity-based compensation award rather than an open-market stock purchase.

How many Evolus (EOLS) shares did David N. Gill acquire in this Form 4?

David N. Gill was granted 45,559 restricted stock units of Evolus common stock. Each RSU represents the right to receive one share upon vesting, so the award corresponds to 45,559 potential shares, subject to the vesting conditions described in the grant terms.

At what price were the Evolus (EOLS) RSUs granted to David N. Gill?

The restricted stock units granted to David N. Gill carried a stated price of $0.00 per share. This indicates they were an equity compensation grant, not a purchase in the open market, and any value to him depends on the company’s share price when the RSUs vest and settle.

When do David N. Gill’s Evolus (EOLS) RSUs vest?

The RSUs granted to David N. Gill will vest in full on the one-year anniversary of February 17, 2026. Vesting is contingent on him remaining in continuous service through that date, with potential accelerated vesting upon certain qualifying change-of-control or similar events affecting Evolus.

What are David N. Gill’s total Evolus (EOLS) holdings after this RSU grant?

After the reported grant, David N. Gill directly holds 86,887 shares or share-equivalent RSUs of Evolus common stock. This total reflects his ownership position immediately following the 45,559-unit RSU award disclosed in the Form 4 insider transaction filing.

Are David N. Gill’s new Evolus (EOLS) RSUs subject to conditions?

Yes. The RSUs granted to David N. Gill are contingent rights that vest only if he remains in continuous service until the one-year anniversary of February 17, 2026. The grant also allows for accelerated vesting upon certain specified change-of-control or similar corporate events involving Evolus.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GILL DAVID N

(Last) (First) (Middle)

520 NEWPORT CENTER DR.

SUITE 1200

(Street)

NEWPORT BEACH CA 92660

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Evolus, Inc. [ EOLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		45,559(1)	A	$0	86,887	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 17, 2026, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer.

Remarks:

	/s/ Jeffrey J. Plumer, as attorney-in-fact for David N. Gill	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.